Uses (Indications) of Quizartinib Tablet for FLT3-Positive Acute Myeloid Leukemia
Quizar (Quizartinib) is used for the treatment of:
-
Acute Myeloid Leukemia (AML)
-
Patients with FLT3-ITD mutation–positive AML
-
Used in combination with chemotherapy or as maintenance therapy, as prescribed by an oncologist
🟢 How Quizartinib Tablet for FLT3-Positive Acute Myeloid Leukemia Works
Quizar contains Quizartinib, a targeted FLT3 inhibitor.
It blocks abnormal FLT3 signaling in leukemia cells, helping to:
-
Slow cancer cell growth
-
Reduce disease progression
-
Improve treatment response in FLT3-mutated AML patients
🟢 Dosage & Administration
-
Dosage is strictly determined by an oncologist
-
Taken orally, with or without food
-
Do not change dose or stop medication without medical advice
🟢 Possible Side Effects
Common side effects may include:
-
Nausea or vomiting
-
Diarrhea
-
Fatigue
-
Low blood cell counts
-
Heart rhythm changes (QT prolongation)
⚠️ Regular ECG and blood tests may be required during treatment.
🟢 Precautions & Warnings
-
For prescription use only
-
Not recommended during pregnancy or breastfeeding
-
Use caution in patients with heart disease
-
Avoid self-medication
🟢 Storage Instructions
-
Store below 30°C
-
Keep away from moisture and direct sunlight
-
Keep out of reach of children
🟢 Frequently Asked Questions (FAQ)
❓ What is Quizar 17.7 mg Tablet used for?
Quizar is used to treat FLT3-positive Acute Myeloid Leukemia (AML).
❓ Is Quizar a chemotherapy drug?
No. Quizar is a targeted therapy (FLT3 inhibitor), not traditional chemotherapy.
❓ Who manufactures Quizar?
Quizar is manufactured by Everest Pharmaceuticals Ltd., Bangladesh.
❓ Can Quizar be taken daily?
Yes, but only as prescribed by an oncologist.
❓ Is genetic testing required before using Quizar?
Yes. FLT3 mutation testing is required before starting treatment.
